Cirrus Pharmaceuticals to Invest in cGMP Manufacturing Suite in US

Cirrus Pharmaceuticals has announced it will be investing in a flexible current good manufacturing practice (cGMP) suite in its facility in Research Triangle Park (RTP), North Carolina.

Kemwell president of R&D Ninad Deshpanday said: "We will offer our clients cGMP manufacturing services for many dosage forms including inhalation, liquids, topicals and oral solids.

"We have completed the design phase and expect the suite to be ready to service customers by April 2015."

Kemwell’s R&D division employs more than 175 scientists worldwide and provides services including formulation development, analytical development and validation to clinical trial manufacturing.

The team has experience working on early stage development programs for National Center for Education Statistics (NCEs), Abbreviated New Drug Applications (ANDAs), 505(b)(2) and product life cycle management projects for various customers worldwide, including virtual, small and big pharmaceuticals.

With the addition of the cGMP suite, Cirrus will extend its offerings in the US from contract development to manufacturing.